Bi-Coastal Pharma International
Form 483 issued January 14, 2022 · Shrewsbury, New Jersey
- Inspection
- Dec 15, 2021 – Jan 14, 2022
- Investigators
- Guerlain Ulysse· Rose Jean-Mary
- Observations
- 1
- Pages
- 8
In short: On January 14, 2022, FDA issued a Form 483 with 1 observation to Bi-Coastal Pharma International in Shrewsbury, New Jersey after an inspection that ran Dec 15, 2021 – Jan 14, 2022. The investigators were Guerlain Ulysse and Rose Jean-Mary. Most observations concern quality system; the most-cited regulation is 21 CFR 211.22 (responsibilities of quality control unit).
At a glance
1 of 1 observations on this 483 concern quality system.
Most cited: 21 CFR 211.22 (1×)
What FDA observed
Preview: the opening words of each observationDashed: section inferred by FDA Intel and checked against the regulation text
- 01
The responsibilities and procedures applicable to the quality control unit are not in…
This inspection in context
Guerlain Ulysse
32 documents · 2016–2026
Cites 211.192 (production record review) more than any other section. Most of their documents are for sites in India.
The firmBi-Coastal Pharma International history
The site's inspection history, in date order.
Similar 483sOther sites cited under 211.22
See how FDA wrote the same problem up elsewhere.
Questions about this 483
What did FDA find at Bi-Coastal Pharma International?
FDA listed 1 observation on this Form 483, mostly about quality system. The most-cited regulation is 21 CFR 211.22 (responsibilities of quality control unit). The opening words of each observation are shown on this page.
Who inspected Bi-Coastal Pharma International?
Guerlain Ulysse and Rose Jean-Mary are named on this Form 483, for the inspection of Dec 15, 2021 – Jan 14, 2022. Each investigator has a profile showing what they cite most.
When was Bi-Coastal Pharma International inspected by FDA?
The inspection ran Dec 15, 2021 – Jan 14, 2022, and the Form 483 is dated January 14, 2022.
How do I get the full Form 483 for Bi-Coastal Pharma International?
Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.